Chwilio Deddfwriaeth

Chwiliad Uwch

Commission Decision of 25 August 2005 declaring a concentration compatible with the common market and the functioning of the EEA Agreement (Case COMP/M.3687 — Johnson & Johnson/Guidant) (notified under document number C(2005) 3230) (Only the English text is authentic) (Text with EEA relevance) (2006/430/EC)

Help about what version

Pa Fersiwn

Help about UK-EU Regulation

Deddfwriaeth yn deillio o’r UE

Pan adawodd y DU yr UE, cyhoeddodd legislation.gov.uk ddeddfwriaeth yr UE a gyhoeddwyd gan yr UE hyd at ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.). Ar legislation.gov.uk, mae'r eitemau hyn o ddeddfwriaeth yn cael eu diweddaru'n gyson ag unrhyw ddiwygiadau a wnaed gan y DU ers hynny.

Close

Mae'r eitem hon o ddeddfwriaeth yn tarddu o'r UE

Mae legislation.gov.uk yn cyhoeddi fersiwn y DU. Mae EUR-Lex yn cyhoeddi fersiwn yr UE. Mae Archif Gwe Ymadael â’r UE yn rhoi cipolwg ar fersiwn EUR-Lex o ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.).

Changes to legislation:

Roedd y fersiwn hon o'r Penderfyniad hwn yn deillio o EUR-Lex ar ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11: 00 p.m.). Nid yw wedi cael ei diwygio gan y DU ers hynny. Darganfyddwch fwy am ddeddfwriaeth sy'n deillio o'r UE fel y'i cyhoeddwyd ar legislation.gov.uk. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

  1. Introductory Text

  2. I. INTRODUCTION

    1. (1) On 15 March 2005, the Commission received a notification of...

      1. On 15 March 2005, the Commission received a notification of...

    2. A. The Parties

      1. (2) J & J is a company incorporated in the USA....

        1. J & J is a company incorporated in the USA....

      2. (3) Guidant is a company incorporated in the United States of...

        1. Guidant is a company incorporated in the United States of...

    3. B. The operation

      1. (4) The concentration is an acquisition of sole control by J & J...

        1. The concentration is an acquisition of sole control by J & J...

  3. II. THE RELEVANT MARKETS

    1. (5) The market investigation confirmed that the areas mostly affected by...

      1. The market investigation confirmed that the areas mostly affected by...

    2. A. The relevant product markets

      1. 1. Interventional cardiology devices

        1. (6) Interventional cardiology devices are designed to treat, through minimally invasive...

          1. Interventional cardiology devices are designed to treat, through minimally invasive...

        2. (7) Bare metal stents (BMS) and drug eluting stents (DES) are...

          1. Bare metal stents (BMS) and drug eluting stents (DES) are...

        3. (8) Concerning the accessories coronary guiding catheters, coronary steerable guidewires, coronary...

          1. Concerning the accessories coronary guiding catheters, coronary steerable guidewires, coronary...

      2. 2. Endovascular devices

        1. (9) Endovascular devices are used for the minimally invasive treatment of...

          1. Endovascular devices are used for the minimally invasive treatment of...

        2. (10) Similar to interventional cardiology stents, endovascular stents are small expandable...

          1. Similar to interventional cardiology stents, endovascular stents are small expandable...

        3. (11) The parties submitted, and the Commission’s market inquiry confirmed, that...

          1. The parties submitted, and the Commission’s market inquiry confirmed, that...

        4. (12) As far as the accessories are concerned, endovascular guiding catheters,...

          1. As far as the accessories are concerned, endovascular guiding catheters,...

      3. 3. Cardiac surgery devices

        1. (13) Coronary artery bypass graft surgery (CABG) is used to treat...

          1. Coronary artery bypass graft surgery (CABG) is used to treat...

        2. (14) The following markets are affected in the cardiac surgery area:...

          1. The following markets are affected in the cardiac surgery area:...

    3. B. The relevant geographic markets

      1. (15) The market investigation confirmed that relevant geographic markets are all...

        1. The market investigation confirmed that relevant geographic markets are all...

  4. III. COMPETITIVE ASSESSMENT

    1. A. Interventional cardiology

      1. (16) Interventional cardiology is a relatively recent, innovation driven business which...

        1. Interventional cardiology is a relatively recent, innovation driven business which...

      2. (17) In the area of interventional cardiology there are two leagues...

        1. In the area of interventional cardiology there are two leagues...

      3. 1. Drug-eluting stents

        1. (18) In the market for DES, the concentration would result in...

          1. In the market for DES, the concentration would result in...

        2. (19) Despite the fact that there is an indication that Guidant...

          1. Despite the fact that there is an indication that Guidant...

        3. (20) The Commission, therefore, concluded that the notified concentration does not...

          1. The Commission, therefore, concluded that the notified concentration does not...

      4. 2. Steerable guidewires

        1. (21) In the interventional cardiology market for steerable guidewires virtually all...

          1. In the interventional cardiology market for steerable guidewires virtually all...

      5. 3. Conclusion

        1. (22) The Commission, therefore, concluded that the notified concentration raises serious...

          1. The Commission, therefore, concluded that the notified concentration raises serious...

    2. B. Endovascular devices

      1. (23) Both J & J and Guidant are leading suppliers in...

        1. Both J & J and Guidant are leading suppliers in...

      2. (24) In the endovascular market for balloon expandable stents, at EEA...

        1. In the endovascular market for balloon expandable stents, at EEA...

      3. (25) When looking at the relevant geographic markets, i.e. each Member...

        1. When looking at the relevant geographic markets, i.e. each Member...

      4. (26) Having regard to the fact that the merger combines the...

        1. Having regard to the fact that the merger combines the...

      5. (27) In the endovascular market for Carotid stents in the EEA,...

        1. In the endovascular market for Carotid stents in the EEA,...

      6. (28) There are three main players in the carotid stent market:...

        1. There are three main players in the carotid stent market:...

      7. (29) In the above national markets, given the degree of concentration,...

        1. In the above national markets, given the degree of concentration,...

      8. (30) In the endovascular devices market for non-carotid stents, the Member...

        1. In the endovascular devices market for non-carotid stents, the Member...

      9. (31) With regard to non-carotid SX stents in the above national...

        1. With regard to non-carotid SX stents in the above national...

      10. (32) The Commission, therefore, concluded that the notified concentration raises serious...

        1. The Commission, therefore, concluded that the notified concentration raises serious...

    3. C. Cardiac surgery: endoscopic vessel harvesting systems

      1. (33) The EEA sales of EVH systems are significantly lower than...

        1. The EEA sales of EVH systems are significantly lower than...

      2. (34) The Commission, therefore, concluded that the notified concentration raises serious...

        1. The Commission, therefore, concluded that the notified concentration raises serious...

  5. IV. COMMITMENTS OFFERED BY THE PARTIES

    1. (35) In order to address the aforementioned competition concerns in the...

      1. in the steerable guidewires business, the parties propose to divest...

  6. V. ASSESSMENT OF THE COMMITMENTS SUBMITTED

    1. (36) As confirmed by the results of the market test conducted...

      1. As confirmed by the results of the market test conducted...

    2. (37) The Commission, therefore, reached the conclusion that, on the basis...

      1. The Commission, therefore, reached the conclusion that, on the basis...

  7. VI. CONCLUSION

    1. (38) For the reasons set out above, the Commission concluded that...

      1. For the reasons set out above, the Commission concluded that...

Yn ôl i’r brig

Options/Cymorth

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill

Mae'r data ar y dudalen hon ar gael yn y fformatau data amgen a restrir: